

Daily evidence digest

1 February 2022

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Tocilizumab and corticosteroids, memory B cells after triple vaccination, readmissions and deaths post COVID-19 hospitalisation

Peer reviewed journals featured:

- Systematic reviews on:
 - Tocilizumab and corticosteroid therapy in treating COVID-19 patients [here](#)
 - Neutralising monoclonal antibodies in COVID-19 outpatients [pre-Omicron] [here](#)
- A randomised controlled trial of hyperimmune immunoglobulin for hospitalised patients [here](#)
- A narrative review on memory B cell repertoire from triple vaccinees against SARS-CoV-2 [here](#)
- Observational studies on:
 - Hospitalisation and death after COVID-19 hospitalisation in England [here](#)
 - Three exposures to SARS-CoV-2 spike protein by infection or vaccination elicit superior neutralising immunity to all variants of concern [here](#)
 - Impact of vaccination on the COVID-19 pandemic in the US [here](#)
 - Persistence of SARS-CoV-2 protection up to 9 months after vaccine completion [here](#)
- Commentary on:
 - Condition specific patient reported outcome measures for post-acute COVID-19 [here](#)
 - A call to action for translational sciences in COVID-19 and future pandemics [here](#)

Letters and correspondence discussed:

- Frequency and risk of emergency medical service interhospital transportation of patients with acute lower respiratory tract illness in COVID-19 in the US [here](#)

Pre-peer review articles featured:

- Omicron-related travel policy restrictions [here](#)
- A qualitative study of the impact of delaying surgery during COVID-19 [here](#)
- Omicron and Delta breakthrough infections and re-activation of vaccine-induced immunity [here](#)
- Omicron in highly vaccinated university populations in Massachusetts [here](#)
- Characteristics and severity of Omicron variant cases in ICU hospital admissions in Paris [here](#)
- Displacement of the SARS-CoV-2 variant Delta with Omicron in the US [here](#)
- mRNA vaccine boosting in patients with antibody deficiency syndromes [here](#)
- Total and neutralising SARS-CoV-2 spike antibodies after 2 or 3 doses of mRNA vaccine [here](#)

- Mucosal immunity against SARS-CoV-2 variants of concern following vaccination [here](#)
- Impact of various vaccine boosters on neutralisation against Omicron following prime vaccinations with inactivated or adenovirus-vectored vaccine [here](#)
- The spread of the Omicron variant in Italy [here](#)
- Hybrid immunity from Delta variant surge and neutralising antibodies against Omicron variant [here](#)

Guidance and reports

- The UK Health Security Agency published an update on SARS-CoV-2 variants of concern and variants under investigation [here](#)

News and blogs

- Unravelling the conundrum of Omicron and deaths [here](#)
- Antibody “signature” could predict the risk of post-acute COVID-19 syndrome [here](#)
- Does the world need an Omicron vaccine? [here](#)
- A podcast on why T cells have been overlooked [here](#)
- Three, four, or more - what’s the magic number for booster shots? [here](#)
- Three key theories on where Omicron came from [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).